CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 248 enrolled
Drug / intervention
Reciferceptother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05659719
NCT05659719N/ACompleted
CompareCT.gov

A Pilot Project to Evaluate the Feasibility of Constructing a Concurrent External Control for Recifercept

Pfizer·observational·Posted Dec 21, 2022·Updated Sep 20, 2024

In Brief

An observational study evaluating Recifercept for Achondroplasia. Completed, enrolled 248 participants across 1 site.

Detailed Summary

The purpose of this study is to learn about the study medicine (called recifercept) in people with achondroplasia. Achondroplasia is a very rare disease and patients of achondroplasia have short arms and legs. The study will include data already collected from a recifercept clinical trial and data collected from a separate study of achondroplasia. This study will compare patient experiences and will help the investigators determine if the study medicine, recifercept, is effective.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAchondroplasia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedDec 21, 2022
Enrollment StartOct 19, 2022
Primary CompletionMay 16, 2023
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 3.5 years ago

Interventions

Reciferceptother

Patients received recifercept intervention in the phase 2 clinical trial